Abstract 304P
Background
The EXTREME trial demonstrated that patients with R/M-HNSCC benefit from the addition of cetuximab to first-line platinum-based CT in relation to overall survival (OS), progression-free survival (PFS) and response rate. The aims of the study are to evaluate the survival outcomes and identify predictors of survival among these patients (pts).
Methods
Data regarding R/M HNSCC consecutive pts treated with cetuximab and platinum from 2009 to 2018 were retrospectively collected. The analyses of response (R.), PFS and OS, each evaluated starting from first treatment, were performed. A Cox proportional hazard model was run and Survival curves were estimated with the Kaplan-Meier method and compared using the log-rank test.
Results
108 pts were identified with ECOG-PS 0-1. Median age was 57 years (y.) (36-74y.) Primary tumor sites were oropharynx 28(25,9%), oral cavity 19 (17,6%), larynx/hypopharynx 57 (52,7%) and others 4 (3,7%). Median OS was 16,9 months (m). (95% confidence interval [CI] 12,9-20,9), and mean PFS was 7,4 m. (95% CI 4,1-8,9). 43 pts (39,8%) completed 6 cycles of treatment. R. rate (partial R. and complete R.) was 19%, with 31 (28,7%) showing stable disease. ECOG-PS 1 (HR = 1.71,95% CI 1,1-2,97) and the location of the primary tumor in the larynx/hypopharynx (HR = 1.98, 95% CI 1,14-3,48) were significantly associated with an increased risk of disease progression.48 (44%) pts who received CT plus cetuximab continued to receive cetuximab until disease progression or unacceptable toxic effects with statistical significant differences between this sub-group and those who weren’t able to receive Cetuximab monotherapy (OS 23,6m. (95% CI 16,1-31,1) vs 10,9 m. (95% CI 8,7-13,1) p = 0,001). OS was higher in pts with grade 2-4 skin toxicity associated with cetuximab (OS 18,4m. (95% CI 13.7-23.1) vs 13,7m. (95% CI 8,7-18,8) p = 0.05).
Conclusions
In non-selected R/M HNSCC pts, we obtained a median PFS and OS of 7,4 and 16,9 months, superior to 5,6 and 10,1 months reported in Extreme trial (Vermorken et al. 2008). ECOG PS, larynx/hypopharynx location and skin toxicity related to Cetuximab could be used to define pt prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract